New approaches to diagnostics and therapy of vascular dementia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Vascular dementia (VD) is a significant public health problem, especially given the aging of the world population.

Based on publications from the PubMed, Scopus and Google Scholar databases up to February 2024, a descriptive review of the current literature on VD was performed. The concept of what qualifies as VD has changed significantly since the first mention of dementia after apoplexy in ancient literature. Modern understanding points to a multifactorial cause of cognitive decline in old age, in which vascular components such as atherosclerosis, infarctions and amyloid angiopathy play an important role along with other markers of neurodegeneration. New diagnostic approaches, advanced neuroimaging methods play a key role in identifying and differentiating vascular disorders from other types of dementia. This allows for a more accurate assessment of the extent and location of vascular lesions, which is very important for correct diagnosis and treatment planning. Integration of data from various studies and clinical practice helps in developing unified and effective treatment strategies for this complex disease. In general, progress in understanding the pathophysiology of VD and the development of new diagnostic and therapeutic approaches open up new opportunities to improve patient care and reduce the overall burden of dementia in society.

Full Text

Restricted Access

About the authors

I. V. Kolykhalov

Research Center for Mental Health

Author for correspondence.
Email: ikolykhalov@yandex.ru
ORCID iD: 0000-0002-2358-1579

Dr. Sci. (Med.)

Russian Federation, Moscow

References

  1. World Health Organization. Diagnostic criteria for research. Geneva: World Health Organization; 1993. The ICD-10 classification of mental and behavioural disorders.
  2. Wepfer J.J. Observationes anatomicae, ex cadaveribus eorum, quos sustulit apoplexia. Cum exercitatione de ejus loco affecto. Schaffhausen, Joh Caspari Suteri; 1658.
  3. Kraepelin E. Psychiatrie: ein Lehrbuch fьr Studierende und Дrzte. Leipzig: Barth;1910. 684 p.
  4. Wolters F.J., Ikram M.A. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542–49. doi: 10.1161/ATVBAHA.119.311908.
  5. Akhter F., Persaud A., Zaokari Y., et al. Vascular Dementia and Underlying Sex Differences.Front Aging Neurosci. 2021;13:720715. doi: 10.3389/fnagi.2021.720715.
  6. Azarpazhooh M.R., Avan A., Cipriano L.E., et al. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimer’s Dement. 2018;14:148–56. doi: 10.1016/j.jalz.2017.07.755.
  7. Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(5):3708–821. doi: 10.1002/alz.13809.
  8. Pendlebury S.T., Rothwell P.M. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: Analysis of the population-based Oxford Vascular Study. Lancet Neurol. 2019;18:248–58. doi: 10.1016/S1474-4422(18)30442-3.
  9. Livingston G., Huntley J., Sommerlad A., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413–46. doi: 10.1016/S0140-6736(20)30367-6.
  10. Diniz B.S., Butters M.A., Albert S.M., et al. Late-life depression and risk of vascular dementia and Alzheimer’s disease: Systematic review and meta-analysis of community-based cohort studies. Br. J. Psychiatry. 2013;202:329–35. doi: 10.1192/bjp.bp.112.118307.
  11. Iadecola C. The Pathobiology of Vascular Dementia. Neuron. 2013;80:844–66. doi: 10.1016/j.neuron.2013.10.008.
  12. Liu Q., Zhu Z., Teipel S.J., Yang J., et al. White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Front. Aging Neurosci. 2017;9:47. doi: 10.3389/fnagi.2017.00047.
  13. Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia. 1994;5(3-4):189–92. doi: 10.1159/000106721.
  14. Ampil E.R., Ong P.A., Krespi Y., Yang Y.H. A review of SaiLuoTong (MLC-SLT) development in vascular cognitive impairment and dementia. Front Pharmacol. 2024;15:1343820. doi: 10.3389/fphar.2024.1343820.
  15. Rundek T., Tolea M., Ariko T., et al. Vascular Cognitive Impairment (VCI). Neurotherapeutics. 2022;19(1):68–88. doi: 10.1007/s13311-021-01170-y.
  16. Skrobot O.A., Black S.E., Chen C., et al. VICCCS group; Ben-Shlomo Y., Passmore A.P., Love S., Kehoe P.G. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018;14(3):280–92. doi: 10.1016/j.jalz.2017.09.007.
  17. Badji A., Youwakim J., Cooper A., et al. Vascular cognitive impairment - Past, present, and future challenges. Ageing Res Rev. 2023;90:102042. doi: 10.1016/j.arr.2023.102042.
  18. MacDonald M.E., Pike G.B. MRI of healthy brain aging: a review. NMR Biomed 2021;34:e4564. doi: 10.1002/nbm.4564.
  19. Heiss W.D., Rosenberg G.A., Thiel A., et al. Neuroimaging in vascular cognitive impairment: a state-of-the-art review. BMC Med. 2016;14(1):174. doi: 10.1186/s12916-016-0725-0.
  20. Heiss W.D. The Additional Value of PET in the Assessment of Cerebral Small Vessel Disease. J Nucl Med. 2018;59(11):1660–64. doi: 10.2967/jnumed.118.21427.
  21. Frantellizzi V., Pani A., Ricci M., et al. Neuroimaging in Vascular Cognitive Impairment and Dementia: A Systematic Review. J Alzheimers Dis. 2020;73(4):1279–94. doi: 10.3233/JAD-191046.
  22. Hamilton O.K.L., Backhouse E.V., Janssen E., et al. Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta-analysis. Alzheimers Dement. 2021;17(4):665–85. doi: 10.1002/alz.12221.
  23. Bir S.C., Khan M.W., Javalkar V., et al. Emerging Concepts in Vascular Dementia: A Review. J Stroke Cerebrovasc Dis. 2021;30(8):105864. doi: 10.1016/j.jstrokecerebrovasdis.2021.
  24. Gupta M., Dasgupta A., Khwaja G.A., et al. Behavioural and psychological symptoms in poststroke vascular cognitive impairment. Behav Neurol. 2014;2014:430128. doi: 10.1155/2014/430128.
  25. Santos M.A.O., Bezerra L.S., Correia C.D.C., Bruscky I.S. Neuropsychiatric symptoms in vascular dementia: Epidemiologic and clinical aspects. Dement Neuropsychol. 2018;12(1):40–4. doi: 10.1590/1980-57642018dn12-010006.
  26. Sun M.K. Potential therapeutics for vascular cognitive impairment and dementia. Curr Neuropharmacol. 2018;16(7):1036–44. doi: 10.2174/1570159X15666171016164734.
  27. Yu W., Li Y., Hu J., et al. A study on the pathogenesis of vascular cognitive impairment and dementia: the chronic cerebral hypoperfusion hypothesis. J Clin Med. 2022;11(16):4742. doi: 10.3390/jcm11164742.
  28. Ткачева О.Н., Мхитарян Э.А., Колыхалов И.В. и др. Лечение когнитивных, психических и поведенческих нарушений у пациентов с сосудистой деменцией: результаты многоцентрового рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(7):41–9. [Tkacheva O.N., Mkhitaryan E.A., Kolykhalov I.V., et al. Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(7):41–9. (In Russ.)]. doi: 10.17116/jnevro202312307141.
  29. Battle C.E., Abdul-Rahim A.H., Shenkin S.D., et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst. Rev. 2021;2(2):CD013306. doi: 10.1002/14651858.CD013306.
  30. Baskys A., Cheng J. Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives. Experimental Gerontol. 2012;47:887–91. doi: 10.1016/j.exger.2012.07.002.
  31. Smith E.E., Barber P., Field T.S., Ganesh A., et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD) 5: Guidelines for management of vascular cognitive impairment. Alzheimer’s Dement. 2020;6:e12056. doi: 10.1002/trc2.12056.
  32. Alam S., Lingenfelter K.S., Bender A.M., Lindsley C.W. Classics in Chemical Neuroscience: Memantine. ACS Chem Neurosci. 2017;8:1823–29. doi: 10.1021/acschemneuro.7b00270.
  33. Folch J., Busquets O., Ettcheto M., et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223–40. doi: 10.3233/JAD-170672.
  34. Parsons C.G., Gilling K.E., Jatzke C. Memantine does not show intracellular block of the NMDA receptor channel. Eur J Pharmacol. 2008;587(1–3):99–103. doi: 10.1016/j.ejphar.2008.03.053.
  35. Farooq M.U., Min J., Goshgarian C., Gorelick P.B. Pharmacotherapy for vascular cognitive impairment. CNS Treatments. 2017;31:759–76. doi: 10.1007/s40263-017-0459-3.
  36. Jin B.R., Liu H.Y. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.Neural Regen Res. 2019;14(5):805–16. doi: 10.4103/1673-5374.249228.
  37. Orgogozo J.M., Rigaud A.S., Stoffler A., et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834–39.doi: 10.1161/01.str.0000020094.08790.49.
  38. Wilcock G., Mцbius H.J., Stцffler A. MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297–305. doi: 10.1097/00004850-200211000-00005.
  39. Любов Е.Б. и группа исследователей. Клинико-функциональный и ресурсосберегающий эффекты лечения акатинолом деменции альцгеймеровского типа и сосудистой деменции. Социальная и клиническая психиатрия. 2009;1:61–73. [Lyubov E.B. et al. Clinical, pharmacoepidemiological and pharmacoecomonic aspects of use of akatinol (memantine) in dementia. Social’naya i klinicheskaya psihiatriya. 2009;1:61–73. (In Russ.)].
  40. Гаврилова С.И., Колыхалов И.В., Михайлова Н.М. и др. Многоцентровое открытое сравнительное рандомизированное исследование эффективности и безопасности применения препарата Акатинол Мемантин, 20 мг (однократный прием) в сравнении с препаратом Акатинол Мемантин, 10 мг (двукратный прием) у пациентов с сосудистой деменцией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(2):69–77. [Gavrilova S.I., Kolykhalov I.V., Mikhaylova N.M., et al. Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(2):69–77. (In Russ.)]. doi: 10.17116/jnevro20241.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media